Long-acting amylin / calcitonin receptor agonist for monotherapy or combination with GLP-1 RA.
Reference facts
- Also known as
- ZP-8396
- Category
- GLP-1 & Metabolic
- Mechanism of action
- Long-acting amylin / calcitonin receptor agonist for monotherapy or combination with GLP-1 RA.
- Targets
- AMY1R, AMY3R, Calcitonin receptor
- Indications under research or approved
- Obesity
- Regulatory status (reference entry)
- Investigational (Phase 2)
- Half-life
- ~7 days
- Sequence notes
- Long-acting amylin analog from Zealand Pharma with proprietary fatty-acid linker.
- Originator / sponsor
- Zealand Pharma
- First reported
- 2023
Primary References
Explore research articles about Petrelintide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.